United States Patent 10,488,413 (Belatacept Early-Phase + Maintenance Regimen in Patients With Elevated CD4+CD57+ T Cells): Claim Strength, Likely Validity Issues, and Landscape
What does US 10,488,413 claim in practice?
US 10,488,413 claims a transplant-treatment method with three technical pillars:
- Patient selection biomarker
- A transplant patient “at risk of costimulation blockade therapy rejection” who has at least a 2-fold increase in CD4+CD57+ T cells versus a normal healthy control (claim 1).
- Drug and dosing regimen
- Belatacept is administered under an early phase regimen plus a maintenance phase regimen (claim 1).
- Early phase dosing: 10 mg/kg during the first three to six months post-transplantation (claim 1).
- Maintenance dosing: 5 mg/kg monthly “following the early phase regimen” and continuing “for the life of the transplant” (claim 1).
- Early phase administration schedule
- Claim 2 specifies injections at:
- Day of transplant
- ~96 hours post-transplant
- 2 weeks
- 4 weeks
- 8 weeks
- 12 weeks
- Claim 3 adds additional early-phase doses:
- 16 weeks
- 20 weeks
- 24 weeks
These claims are broad on what a transplant can be (solid organ, tissue, or cell; claim 4) and then narrow by listing exemplar organs/tissues (claim 5) and a kidney embodiment (claim 6).
Is the CD4+CD57+ selection element a patentable discriminator or a vulnerability?
How the claim frames the biomarker
The biomarker is not used to define an assay method, thresholds beyond “2-fold,” or a clinical endpoint. It functions as an eligibility condition:
- Eligibility: “at least a 2-fold increase” in CD4+CD57+ T cells relative to “a normal healthy control” (claim 1).
- Risk basis: being “at risk of costimulation blockade therapy rejection” (claim 1).
Likely prior-art pressure points
The patent’s defensibility turns on whether the combination of:
- CD4+CD57+ as a predictive biomarker for belatacept/costimulation blockade rejection risk, and
- use in a belatacept dosing strategy with specific early and maintenance regimens,
was already disclosed.
Common prior-art patterns that can defeat novelty or obviousness in this kind of claim set:
- Biomarker existence without linkage to belatacept rejection management.
If earlier publications identify CD57+ or senescent T-cell subsets (often CD4+CD57+) in transplant rejection generally, or predict rejection risk under immunosuppression generally, they can be used for obviousness even if not tied to “costimulation blockade therapy” specifically.
- General biomarker-to-decision logic that a skilled person would apply.
If the record includes disclosure that biomarker-high patients benefit from adjusted immunosuppression intensity, then selecting such a biomarker and intensifying belatacept exposure can be treated as an expected optimization rather than a non-obvious leap.
- Ambiguity of assay comparators
“Normal healthy control” is not operationalized in the claims. Prior art can exploit this to challenge enablement or to argue that the “2-fold” metric lacks a standardized analytical method, which can matter for patentability depending on how the disclosure is supported.
Critical claim-design observation
The claim does not require demonstrating that the biomarker is measured at a defined time point (pre-transplant, peri-transplant, longitudinal). It also does not require defining the test conditions or gating strategy. That lowers evidentiary burden for infringement (good for enforcement) but raises patentability risk if broad and earlier.
How strong is novelty for the belatacept dosing components?
What claim 1–3 cover on dosing
Claim 1 and 2 together essentially recite a clinically staged belatacept regimen:
- Early phase: 10 mg/kg within the first 3 to 6 months
- Maintenance: 5 mg/kg monthly “for the life of the transplant”
- Specific early schedule: day 0; ~96 hours; 2, 4, 8, 12 weeks; and in dependent claim 3, also 16, 20, 24 weeks
Prior-art landscape logic (high-level)
Belatacept regimens are widely known in transplantation. If the claimed early-phase schedule overlaps with earlier belatacept labeling or published clinical protocols, then the dosing schedule itself likely fails a strict “novelty-only” defense. The claim may survive novelty only if the dosing regimen is coupled to the specific biomarker-defined patient selection and/or the “risk of costimulation blockade therapy rejection” use.
So the practical strength is often:
- If dosing matches prior art: novelty rests on the CD4+CD57+ criterion and the costimulation-blockade rejection risk targeting.
- If biomarker+rejection targeting is novel: obviousness becomes the main issue, with dosing acting as supporting evidence of predictability but also as prior-art background.
Dependent claims as drafting leverage
Claims 2 and 3 narrow timing and add doses. That can help in enforcement against partial regimen adopters, but it does not automatically cure invalidity if earlier documents disclose the same schedule.
Is claim 1 likely vulnerable to obviousness under a “known regimen + known biomarker” approach?
A common invalidity thesis for this style of claim is:
- Belatacept dosing intensification strategies in early months are disclosed or routine.
- CD4+CD57+ (or CD57+ T subsets) correlate with transplant outcomes and can be measured.
- A skilled person would apply a transplant biomarker risk stratification to adjust belatacept dosing, because costimulation blockade has known immunologic failure modes and clinicians escalate therapies in high-risk phenotypes.
This thesis is particularly strong when:
- prior art ties senescent/exhausted T-cell phenotypes to rejection or poor response under immune suppression, and
- prior art supports that “higher immunologic risk” justifies more frequent or higher initial dosing.
The weak link the challenger will attack
Claim 1 contains a high-level causation statement: the method treats a patient “at risk of costimulation blockade therapy rejection.” If the biomarker does not have a direct evidence chain to belatacept failure, challengers can argue that the risk framing is a label placed on a biomarker association that is not mechanistically or clinically validated for the belatacept context.
Does the “for the life of the transplant” maintenance requirement create additional enforceability?
Yes for scope, but it can also create enforceability disputes:
- Clinically, long-term belatacept use is standard in some protocols, but there can be adjustments (discontinuation for toxicity, switching regimens, tapering in special cases).
- If a competitor uses the regimen for a finite period and then stops, they may argue non-infringement against the literal “life of the transplant” phrasing.
However, enforcement often turns on how the regimen is actually administered in practice across real-world treatment pathways, not just on one-off clinical variations.
How broad is the transplant coverage, and why does that matter for validity and infringement?
Coverage
- Claim 4: transplant can be “solid organ, tissue and/or cell.”
- Claim 5: non-exhaustive list includes skin, islet cells, muscle, hepatocytes, neurons, heart, liver, kidney, lung, appendages, limbs, nose, ear, face.
- Claim 6: transplant is a kidney.
Validity risk from breadth
If evidence supporting the CD4+CD57+ threshold and belatacept regimen effect is kidney-centric, the broader tissue/cell/organ claim set can face:
- Enablement and written description challenges (if the patent’s supporting disclosure does not cover the full breadth with sufficient detail).
- Obviousness arguments using “one organ’s biomarker logic generalizes across transplant types,” which can be attacked if immunology differs materially among organs.
Infringement advantage from breadth
Even if clinical adoption concentrates in kidney, broad claim scope increases leverage in settlement discussions and portfolio blocking, especially against generic dosing label strategies that can be used cross-organ.
Where is the infringement footprint most likely?
A practical assessment based on the claim language:
- Kidney transplant programs
- Highest probability because claim 6 explicitly covers kidney and belatacept uptake is historically concentrated there.
- Centers using structured belatacept initiation schedules
- Claim 2’s specific day/week dosing creates clear matching criteria for structured protocols.
- Patients stratified by CD4+CD57+ elevation
- The biomarker criterion can narrow infringement, but it also creates a bright-line test for whether clinicians are applying the claimed threshold-driven selection.
If a competitor avoids infringement by not measuring CD4+CD57+ or by using different patient stratification criteria, they may steer clear of claim 1. But if they do measure and select, the remaining question becomes whether they mirror the claimed dosing.
What does this mean for the competitive patent landscape (generic and biosimilar strategy)?
Even without external document parsing here, the strategic implications are clear from claim construction:
For belatacept biosimilar developers
- A biosimilar can often match dosing schedules while avoiding selection biomarker language.
- Risk arises if marketing, investigator protocols, or reimbursement-driven guidelines incorporate CD4+CD57+ threshold criteria to manage “risk of costimulation blockade therapy rejection.”
For transplant immunology protocol designers
- If CD4+CD57+ testing becomes part of standard-of-care risk stratification, this patent can become a direct enforcement target.
- Protocol designers can reduce exposure by using alternative biomarkers or non-CD4+CD57+ thresholds or by not using the measured elevation as an eligibility trigger for the specific early dosing pattern.
Claim-by-claim critical reading
Claim 1 (independent)
- Treat a transplant patient at risk of costimulation blockade therapy rejection.
- Provide patient with ≥2-fold increase in CD4+CD57+ T cells versus normal healthy control.
- Administer belatacept with:
- early phase: 10 mg/kg during first 3 to 6 months
- maintenance: 5 mg/kg monthly after early phase, continuing for the life of transplant
Key vulnerability: the evidence linkage between biomarker status and costimulation blockade rejection management must be supported in the record; otherwise obviousness or lack-of-effect arguments can gain traction.
Key enforceability strength: the combination is specific and includes both biomarker selection and a dosing pattern.
Claim 2 (dependent)
- Early phase schedule includes day 0; ~96 hours; 2, 4, 8, 12 weeks.
Enforceability strength: clear timepoints are easy to match against clinical protocols.
Validity risk: if earlier sources disclose that same schedule as standard belatacept initiation, then claim 2 depends almost entirely on the biomarker selection requirement in claim 1.
Claim 3 (dependent)
- Adds 16, 20, 24 weeks dosing.
Enforceability strength: further narrows to a longer early-phase period.
Validity risk: if earlier protocols already include dosing through 24 weeks, the incremental narrowing may not be enough for novelty.
Claims 4–6 (transplant scope)
- Broad across transplant types (claim 4), expanded exemplars (claim 5), and kidney (claim 6).
Validity risk: breadth can outpace evidentiary support.
Enforceability strength: kidney coverage is explicitly claimed.
Key takeaways for business decisions
- The patent’s likely strongest legal hook is the CD4+CD57+ eligibility criterion coupled to a specific belatacept early-to-maintenance regimen. If prior art dosing is common, the biomarker-based selection becomes the center of gravity for validity and infringement.
- The dosing schedule provisions in claims 2–3 are likely to be treated as routine protocol structure unless the biomarker-coupled dosing strategy is uniquely disclosed earlier.
- Broad transplant coverage increases enforcement reach but also increases validity risk if the supporting evidence is not equally persuasive across organs and cell types.
- The maintenance language (“for the life of the transplant”) can create both enforcement opportunity and non-infringement arguments if clinical practice stops or changes belatacept outside the life-of-transplant framing.
Key Takeaways
- US 10,488,413 combines a specific biomarker threshold (CD4+CD57+ ≥2-fold) with a belatacept early-phase (10 mg/kg) and monthly maintenance (5 mg/kg) strategy.
- Dependent claims 2–3 lock in a precise initiation schedule, but these timepoints can be prior-art risks if earlier belatacept protocols match them.
- The claim’s defensibility is most likely to hinge on whether prior literature already disclosed CD4+CD57+ as a belatacept costimulation blockade rejection risk marker that justifies the claimed dosing strategy.
- Breadth across transplant types expands enforcement scope but can increase validity exposure if evidentiary support is organ-specific.
FAQs
-
What patient characteristic does US 10,488,413 require before giving belatacept?
At least a 2-fold increase in CD4+CD57+ T cells versus a normal healthy control.
-
What are the belatacept doses and schedules in the independent claim?
10 mg/kg during the first 3 to 6 months, then 5 mg/kg monthly for the “life of the transplant.”
-
What does claim 2 specify about early-phase dosing timepoints?
Day of transplant, ~96 hours, and weeks 2, 4, 8, and 12.
-
What additional timepoints are added in claim 3?
Weeks 16, 20, and 24.
-
Does the patent limit the claim to kidney transplants?
No. Kidney is one embodiment (claim 6), while claims 4–5 cover broad solid organ, tissue, and cell categories.
References
[1] US Patent 10,488,413, claims 1-6 (as provided in the prompt).